The Journal of Clinical Psychiatry,
Journal Year:
2022,
Volume and Issue:
83(5)
Published: July 29, 2022
Background:
Treatment
resistance
is
a
significant
problem
among
young
people
experiencing
moderate-to-severe
anxiety,
affecting
nearly
half
of
all
patients.
This
study
investigated
the
safety
and
efficacy
cannabidiol
(CBD),
non-intoxicating
component
Cannabis
sativa,
for
anxiety
disorders
in
who
previously
failed
to
respond
standard
treatment.
Methods:
In
this
open-label
trial,
31
aged
12–25
years
with
DSM-5
disorder
no
clinical
improvement
despite
treatment
cognitive-behavioral
therapy
and/or
antidepressant
medication
were
enrolled
between
May
16,
2018,
June
28,
2019.
All
participants
received
add-on
CBD
12
weeks
on
fixed-flexible
schedule
titrated
up
800
mg/d.
The
primary
outcome
was
severity,
measured
Overall
Anxiety
Severity
Impairment
Scale
(OASIS),
at
week
12.
Secondary
outcomes
included
comorbid
depressive
symptoms,
Clinical
Global
Impressions
scale
(CGI)
score,
social
occupational
functioning.
Results:
Mean
(SD)
OASIS
scores
decreased
from
10.8
(3.8)
baseline
6.3
(4.5)
12,
corresponding
−42.6%
reduction
(P
<
.0001).
Depressive
symptoms
.0001),
CGI-Severity
=
.0008),
functioning
.04)
improved
significantly.
Adverse
events
reported
25
(80.6%)
fatigue,
low
mood,
hot
flushes
or
cold
chills.
There
serious
unexpected
adverse
events.
Conclusions:
These
findings
suggest
that
can
reduce
severity
has
an
adequate
profile
treatment-resistant
disorders.
Randomized
controlled
trials
are
needed
confirm
longer-term
compound.
Trial
Registration:
New
Zealand
Trials
Registry
(ANZCTR)
identifier:
ACTRN12617000825358
Biomolecules,
Journal Year:
2020,
Volume and Issue:
10(11), P. 1575 - 1575
Published: Nov. 19, 2020
The
potential
therapeutic
use
of
some
Cannabis
sativa
plant
compounds
has
been
attracting
great
interest,
especially
for
managing
neuropsychiatric
disorders
due
to
the
relative
lack
efficacy
current
treatments.
Numerous
studies
have
carried
out
using
main
phytocannabinoids,
tetrahydrocannabinol
(THC)
and
cannabidiol
(CBD).
CBD
displays
an
interesting
pharmacological
profile
without
becoming
a
drug
abuse,
unlike
THC.
In
this
review,
we
focused
on
anxiolytic,
antidepressant,
antipsychotic
effects
found
in
animal
human
studies.
rodents,
results
suggest
that
depend
dose,
strain,
administration
time
course
(acute
vs.
chronic),
route
administration.
addition,
certain
key
targets
related
with
these
actions,
including
cannabinoid
receptors
(CB1r
CB2r),
5-HT1A
receptor
neurogenesis
factors.
Preliminary
clinical
trials
also
support
as
antipsychotic,
more
importantly,
positive
risk-benefit
profile.
These
promising
development
large-scale
further
evaluate
new
treatment
psychiatric
disorders.
BMC Psychiatry,
Journal Year:
2020,
Volume and Issue:
20(1)
Published: Jan. 16, 2020
Medicinal
cannabis
has
received
increased
research
attention
over
recent
years
due
to
loosening
global
regulatory
changes.
been
reported
have
potential
efficacy
in
reducing
pain,
muscle
spasticity,
chemotherapy-induced
nausea
and
vomiting,
intractable
childhood
epilepsy.
Yet
its
application
the
field
of
psychiatry
is
lesser
known.The
first
clinically-focused
systematic
review
on
emerging
medical
across
all
major
psychiatric
disorders
was
conducted.
Current
evidence
regarding
whole
plant
formulations
plant-derived
cannabinoid
isolates
mood,
anxiety,
sleep,
psychotic
deficit/hyperactivity
disorder
(ADHD)
discussed;
while
also
detailing
clinical
prescription
considerations
(including
pharmacogenomics),
occupational
public
health
elements,
future
recommendations.
The
literature
conducted
during
2019,
assessing
data
from
case
studies
trials
involving
medicinal
or
for
(neurological
conditions
pain
were
omitted).The
present
therapeutics
nascent,
thereby
it
currently
premature
recommend
cannabinoid-based
interventions.
Isolated
positive
have,
however,
revealed
tentative
support
cannabinoids
(namely
cannabidiol;
CBD)
social
anxiety;
with
mixed
(mainly
positive)
adjunctive
use
schizophrenia.
Case
suggest
that
may
be
beneficial
improving
sleep
post-traumatic
stress
disorder,
however
weak.
Preliminary
findings
indicate
no
benefit
depression
high
delta-9
tetrahydrocannabinol
(THC)
therapeutics,
CBD
mania.
One
isolated
study
indicates
some
an
oral
cannabinoid/terpene
combination
ADHD.
Clinical
prescriptive
consideration
involves
caution
high-THC
(avoidance
youth,
people
anxiety
disorders),
gradual
titration,
regular
assessment,
cardiovascular
respiratory
disorders,
pregnancy
breast-feeding.There
encouraging,
albeit
embryonic,
treatment
a
range
disorders.
Supportive
are
key
isolates,
clinicians
need
mindful
safety
considerations,
especially
if
initiating
higher
dose
THC
formulas.
Pharmacology Research & Perspectives,
Journal Year:
2020,
Volume and Issue:
8(6)
Published: Nov. 9, 2020
Abstract
Cannabidiol
(CBD)
is
the
second
most
abundant
component
of
Cannabis
plant
and
known
to
have
effects
distinct
from
Δ
9
‐tetrahydrocannabinol
(THC).
Many
studies
that
examined
behavioral
CBD
concluded
it
lacks
psychotomimetic
attributed
THC.
However,
was
shown
a
broad
spectrum
on
several
conditions
such
as
anxiety,
inflammation,
neuropathic
pain,
epilepsy.
It
currently
thought
engages
different
targets
hence
CBD’s
are
be
due
multiple
molecular
mechanisms
action.
A
well‐accepted
set
include
GPCRs
ion
channels,
with
serotonin
5‐HT
1A
receptor
transient
potential
cation
channel
TRPV1
being
two
main
targets.
has
also
been
target
G
protein‐coupled
receptors
(GPCRs)
cannabinoid
opioid
receptors.
Other
suggested
role
for
additional
channels
CBD.
Currently,
clinical
efficacy
not
completely
understood.
Evidence
derived
randomized
trials,
in
vitro
vivo
models
real‐world
observations
support
use
drug
treatment
option
neuropathy,
many
other
conditions.
Hence
an
understanding
current
status
field
relates
great
interest
so,
this
review,
we
findings
recent
highlight
these
Basic & Clinical Pharmacology & Toxicology,
Journal Year:
2022,
Volume and Issue:
130(4), P. 439 - 456
Published: Jan. 27, 2022
Cannabidiol
(CBD)
is
an
abundant
non-psychoactive
phytocannabinoid
in
cannabis
extracts
which
has
high
affinity
on
a
series
of
receptors,
including
Type
1
cannabinoid
receptor
(CB1),
2
(CB2),
GPR55,
transient
potential
vanilloid
(TRPV)
and
peroxisome
proliferator-activated
gamma
(PPARγ).
By
modulating
the
activities
these
CBD
exhibits
multiple
therapeutic
effects,
neuroprotective,
antiepileptic,
anxiolytic,
antipsychotic,
anti-inflammatory,
analgesic
anticancer
properties.
could
also
be
applied
to
treat
or
prevent
COVID-19
its
complications.
Here,
we
provide
narrative
review
CBD's
applications
human
diseases:
from
mechanism
action
clinical
trials.
International Journal of Molecular Sciences,
Journal Year:
2020,
Volume and Issue:
21(9), P. 3067 - 3067
Published: April 26, 2020
Cannabis
sativa
is
an
aromatic
annual
flowering
plant
with
several
botanical
varieties,
used
for
different
purposes,
like
the
production
of
fibers,
oil
from
seeds,
and
especially
recreational
or
medical
purposes.
Phytocannabinoids
(terpenophenolic
compounds
derived
plant),
include
well-known
psychoactive
cannabinoid
Δ9-tetrahydrocannabinol,
many
non-psychoactive
cannabinoids,
cannabidiol.
The
endocannabinoid
system
(ECS)
comprises
ligands,
enzymes
synthesis
degradation
such
receptors.
This
widely
distributed
in
gastrointestinal
tract,
where
phytocannabinoids
exert
potent
effects,
particularly
under
pathological
(i.e.,
inflammatory)
conditions.
Herein,
we
will
first
look
at
hemp
as
a
possible
source
new
functional
food
ingredients
nutraceuticals
that
might
be
eventually
useful
to
treat
even
prevent
Subsequently,
briefly
describe
ECS
general
pharmacology
phytocannabinoids.
Finally,
revise
available
data
showing
phytocannabinoids,
cannabidiol,
may
disorders
diseases
tract.
With
increasing
interest
development
foods
healthy
life,
are
hoped
find
place
also
tract
function.
Molecules,
Journal Year:
2023,
Volume and Issue:
28(7), P. 3271 - 3271
Published: April 6, 2023
Cannabidiol
(CBD)
is
a
major
phytocannabinoid
present
in
Cannabis
sativa
(Linneo,
1753).
This
naturally
occurring
secondary
metabolite
does
not
induce
intoxication
or
exhibit
the
characteristic
profile
of
drugs
abuse
from
cannabis
like
Δ9-tetrahydrocannabinol
(∆9-THC)
does.
In
contrast
to
∆9-THC,
our
knowledge
neuro-molecular
mechanisms
CBD
limited,
and
its
pharmacology,
which
appears
be
complex,
has
yet
been
fully
elucidated.
The
study
pharmacological
effects
grown
exponentially
recent
years,
making
it
necessary
generate
frequently
updated
reports
on
this
important
metabolite.
article,
rationalized
integration
action
molecular
targets
implications
animal
models
human
diseases,
such
as
epilepsy,
pain,
neuropsychiatric
disorders,
Alzheimer’s
disease,
inflammatory
are
presented.
We
identify
around
56
different
for
CBD,
including
enzymes
ion
channels/metabotropic
receptors
involved
neurologic
conditions.
Herein,
we
compiled
found
scientific
literature
multiple
actions
CBD.
vitro
vivo
findings
essential
understanding
polypharmacological
nature
natural
product.
